Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy

Gavin P Dunn, Timothy F Cloughesy, Marcela V Maus, Robert M Prins, David A Reardon, Adam M Sonabend. Neuro-oncology, Volume 22, Issue 10, 14 October 2020, Pages 1425-1438 Read More


 As immunotherapy assumes a central role in the management of many cancers, ongoing work is directed at understanding whether immune-based treatments will be successful in patients with glioblastoma (GBM). Despite several large studies conducted in the last several years, there remain no FDA-approved immunotherapies in this patient population. Nevertheless, there are a range of exciting new approaches being applied to GBM, all of which may not only allow us to develop new treatments but also help us understand fundamental features of the immune response in the central nervous system. In this review, we summarize new developments in the application of immune checkpoint blockade, from biomarker-driven patient selection to the timing of treatment. Moreover, we summarize novel work in personalized immune-oncology by reviewing work in cancer immunogenomics-driven neoantigen vaccine studies. Finally, we discuss cell therapy efforts by reviewing the current state of chimeric antigen receptor T-cell therapy. © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Full Text


Posted on October 29, 2020
Posted in: Neurogenetics & Transcriptomics, NeuroRestorative Therapy, Publications Authors: